A double-blind, randomized study to evaluate the efficacy and safety of TAK-475 [lapaquistat] 100 mg versus placebo in subjects with primary hypercholesterolemia

Trial Profile

A double-blind, randomized study to evaluate the efficacy and safety of TAK-475 [lapaquistat] 100 mg versus placebo in subjects with primary hypercholesterolemia

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Lapaquistat (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2006 Status change
    • 29 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top